Hyperbaric oxygen therapy (HBOT) is one of the few treatments proven effective for central retinal artery occlusion. Physicians
may also use intravenous (IV) and topical medications or carbogen therapy, a combination of carbon dioxide and oxygen gas, to
reduce pressure and increase blood circulation in the eye. CRAO is a vascular event requiring speedy attention. Proper treatment
in the first 24 hours is critical.
Arterial Insufficiencies: Central Retinal Artery Occlusion
page in the Undersea and Hyperbaric Medical Society resource library to learn more about CRAO, the rationale for hyperbaric
oxygen therapy, and clinical outcomes and success factors.
The retina consumes oxygen at a rate faster than any other organ in the body. It is highly sensitive to ischemia, or lack
of blood supply. In the treatment of CRAO hyperbaric oxygen therapy has succeeded where others in the last 100 years have
[ UHMS ].
But quick access to an emergency-ready chamber is a must. Or as
[ Medscape ]
puts it, “Hyperbaric oxygen therapy (HBOT) may be beneficial if begun within 2-12 hours of symptom onset. Institute
treatment with other interventions first, as transport to a chamber may usurp precious time.” Central retinal artery
occlusion offers yet another good reason, then, for the healthcare community to demand 24/7 access to hyperbaric